Lidocain Grindeks (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve cells, preventing the rapid influx of sodium that initiates an action potential. This stabilizes the neuronal membrane, halting the transmission of pain signals and producing a reversible loss of sensation in the treated area.

The dose of Lidocain Grindeks is determined by the prescribing clinician based on the specific procedure, patient weight, and clinical setting. Healthcare professionals calculate the appropriate volume and concentration to achieve effective anesthesia while minimizing toxicity.

Safety data for lidocaine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when clearly needed, and the prescriber must weigh potential benefits against possible risks to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Lidocaine is a medium‑duration amide‑type local anesthetic, offering rapid onset and moderate length of action. Compared with shorter‑acting agents like procaine, lidocaine provides longer analgesia, while agents such as bupivacaine have a longer duration but a higher risk of cardiotoxicity. Choice depends on procedural needs and safety considerations.

Lidocain Grindeks should be stored at controlled room temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture and extreme temperatures. Do not freeze; inspect the vial for particulate matter before use.

The product is supplied as a sterile solution for injection. It can be administered epidurally, intravenously, or subcutaneously by a qualified healthcare professional using aseptic technique. The route and rate of administration are determined by the clinical indication and patient response.

Serious risks include systemic toxicity manifesting as cardiac arrhythmias, seizures, or methemoglobinemia, as well as severe allergic reactions such as anaphylaxis. Prompt recognition of symptoms and immediate medical intervention are essential to mitigate these potentially life‑threatening events.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid this product. It is also contraindicated in individuals with severe hepatic impairment, certain cardiac conduction disorders, or those receiving interacting Class I antiarrhythmic drugs without close monitoring.